Cross-sectional Multicenter Study Evaluating the IL28B Polymorphism in Patients With HBeAg-negative Chronic Hepatitis B Treated With Pegylated Interferon Alfa-2a in the Course of Peg.Be.Liver Study [SUBSTUDY OF 700013463]
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 09 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2013 Planned End Date changed from 1 Jul 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.